Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00107421 | Liver | Cirrhotic | macrophage derived foam cell differentiation | 19/4634 | 38/18723 | 6.75e-04 | 5.06e-03 | 19 |
GO:00900771 | Liver | Cirrhotic | foam cell differentiation | 19/4634 | 38/18723 | 6.75e-04 | 5.06e-03 | 19 |
GO:0010745 | Liver | Cirrhotic | negative regulation of macrophage derived foam cell differentiation | 9/4634 | 13/18723 | 9.10e-04 | 6.49e-03 | 9 |
GO:00091416 | Liver | Cirrhotic | nucleoside triphosphate metabolic process | 43/4634 | 112/18723 | 9.31e-04 | 6.62e-03 | 43 |
GO:00199151 | Liver | Cirrhotic | lipid storage | 35/4634 | 87/18723 | 1.03e-03 | 7.20e-03 | 35 |
GO:0010888 | Liver | Cirrhotic | negative regulation of lipid storage | 13/4634 | 23/18723 | 1.12e-03 | 7.70e-03 | 13 |
GO:00725225 | Liver | Cirrhotic | purine-containing compound biosynthetic process | 69/4634 | 200/18723 | 1.22e-03 | 8.24e-03 | 69 |
GO:001056511 | Liver | Cirrhotic | regulation of cellular ketone metabolic process | 49/4634 | 133/18723 | 1.25e-03 | 8.41e-03 | 49 |
GO:009728411 | Liver | Cirrhotic | hepatocyte apoptotic process | 10/4634 | 16/18723 | 1.51e-03 | 9.91e-03 | 10 |
GO:00427525 | Liver | Cirrhotic | regulation of circadian rhythm | 45/4634 | 121/18723 | 1.55e-03 | 1.01e-02 | 45 |
GO:000614011 | Liver | Cirrhotic | regulation of nucleotide metabolic process | 34/4634 | 86/18723 | 1.71e-03 | 1.09e-02 | 34 |
GO:0010743 | Liver | Cirrhotic | regulation of macrophage derived foam cell differentiation | 16/4634 | 32/18723 | 1.77e-03 | 1.13e-02 | 16 |
GO:00061645 | Liver | Cirrhotic | purine nucleotide biosynthetic process | 65/4634 | 191/18723 | 2.42e-03 | 1.46e-02 | 65 |
GO:19059521 | Liver | Cirrhotic | regulation of lipid localization | 62/4634 | 181/18723 | 2.53e-03 | 1.51e-02 | 62 |
GO:00091446 | Liver | Cirrhotic | purine nucleoside triphosphate metabolic process | 34/4634 | 88/18723 | 2.68e-03 | 1.57e-02 | 34 |
GO:00091425 | Liver | Cirrhotic | nucleoside triphosphate biosynthetic process | 33/4634 | 85/18723 | 2.81e-03 | 1.63e-02 | 33 |
GO:19040191 | Liver | Cirrhotic | epithelial cell apoptotic process | 44/4634 | 121/18723 | 2.86e-03 | 1.65e-02 | 44 |
GO:190384411 | Liver | Cirrhotic | regulation of cellular response to transforming growth factor beta stimulus | 47/4634 | 131/18723 | 2.87e-03 | 1.65e-02 | 47 |
GO:000717811 | Liver | Cirrhotic | transmembrane receptor protein serine/threonine kinase signaling pathway | 111/4634 | 355/18723 | 2.98e-03 | 1.70e-02 | 111 |
GO:00170152 | Liver | Cirrhotic | regulation of transforming growth factor beta receptor signaling pathway | 46/4634 | 128/18723 | 3.04e-03 | 1.72e-02 | 46 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05415 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa04932 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa04922 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa05160 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa054151 | Colorectum | AD | Diabetic cardiomyopathy | 114/2092 | 203/8465 | 3.65e-22 | 3.06e-20 | 1.95e-20 | 114 |
hsa049321 | Colorectum | AD | Non-alcoholic fatty liver disease | 90/2092 | 155/8465 | 4.83e-19 | 1.80e-17 | 1.15e-17 | 90 |
hsa049221 | Colorectum | AD | Glucagon signaling pathway | 41/2092 | 107/8465 | 1.18e-03 | 7.75e-03 | 4.94e-03 | 41 |
hsa051601 | Colorectum | AD | Hepatitis C | 54/2092 | 157/8465 | 3.87e-03 | 1.96e-02 | 1.25e-02 | 54 |
hsa054152 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
hsa049322 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
hsa049222 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa054153 | Colorectum | SER | Diabetic cardiomyopathy | 103/1580 | 203/8465 | 1.45e-25 | 1.61e-23 | 1.17e-23 | 103 |
hsa049323 | Colorectum | SER | Non-alcoholic fatty liver disease | 75/1580 | 155/8465 | 2.16e-17 | 5.99e-16 | 4.35e-16 | 75 |
hsa049223 | Colorectum | SER | Glucagon signaling pathway | 38/1580 | 107/8465 | 2.57e-05 | 3.28e-04 | 2.38e-04 | 38 |
hsa054158 | Colorectum | FAP | Diabetic cardiomyopathy | 70/1404 | 203/8465 | 2.62e-10 | 2.18e-08 | 1.33e-08 | 70 |
hsa049328 | Colorectum | FAP | Non-alcoholic fatty liver disease | 54/1404 | 155/8465 | 1.98e-08 | 6.20e-07 | 3.77e-07 | 54 |
hsa049226 | Colorectum | FAP | Glucagon signaling pathway | 32/1404 | 107/8465 | 4.08e-04 | 3.10e-03 | 1.89e-03 | 32 |
hsa049312 | Colorectum | FAP | Insulin resistance | 32/1404 | 108/8465 | 4.90e-04 | 3.56e-03 | 2.16e-03 | 32 |
hsa04024 | Colorectum | FAP | cAMP signaling pathway | 51/1404 | 225/8465 | 1.02e-02 | 3.68e-02 | 2.24e-02 | 51 |
hsa054159 | Colorectum | FAP | Diabetic cardiomyopathy | 70/1404 | 203/8465 | 2.62e-10 | 2.18e-08 | 1.33e-08 | 70 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
PPARA | MVA | Breast | Healthy | TNFRSF4,SH3TC1,SLFN11, etc. | 1.51e-01 | |
PPARA | MVA | Breast | Precancer | TNFRSF4,SH3TC1,SLFN11, etc. | 2.91e-01 | |
PPARA | PVA | Breast | Precancer | TNFRSF4,SH3TC1,SLFN11, etc. | 2.39e-01 | |
PPARA | cDC | Lung | IAC | CEP112,PIGL,AL683807.1, etc. | 1.94e-02 | |
PPARA | M1MAC | Prostate | Healthy | SLC18B1,PTPN9,TGFBR1, etc. | 1.52e-01 | |
PPARA | PTC | Thyroid | ADJ | CCDC69,SAA2,USP43, etc. | 2.14e-01 | |
PPARA | TFC | Thyroid | ATC | CCDC69,SAA2,USP43, etc. | 8.84e-02 | |
PPARA | iATC | Thyroid | ATC | CCDC69,SAA2,USP43, etc. | 1.25e-01 | |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | T091317 | T091317 | 20350005 |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | simvastatin | SIMVASTATIN | 23930676,24598718,23252946 |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | BMS-687453 | CHEMBL1089501 | 20218621 |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | GTF505 | | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | ZYH-1 | | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135650110 | CLOFIBRATE | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | GFT14 | | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | agonist | 135650558 | LY-510929 | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | OLEIC ACID | OLEIC ACID | |
5465 | PPARA | TRANSCRIPTION FACTOR, ENZYME, DRUGGABLE GENOME, NUCLEAR HORMONE RECEPTOR | | CIPROFIBRATE | CIPROFIBRATE | |